Post hoc analysis of the phase 2 OPRA trial in 303 patients with stage II/III rectal adenocarcinoma: a high-dose vs standard-dose radiation boost was not significantly associated with clinical complete response or 5-year organ preservation (45% vs 52%).
Secondary analysisn = 303
Yariv et al. Does Radiation Boost Dose Affect Organ Preservation Rates? A Secondary Analysis of the Organ Preservation in Patients With Rectal Adenocarcinoma Trial